SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma enters into distribution services agreement with AZPIL

02 Jun 2015 Evaluate

Sun Pharmaceutical Industries has entered into a distribution services agreement with AstraZeneca Pharma India (AZPIL) for AstraZeneca’s brand ‘Axcer’, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS).

AZPIL already has a brand under the trademark ‘Brilinta’, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.

Sun Pharma will be promoting and distributing ‘Axcer’ brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy. 


Sun Pharma Inds. Share Price

1670.35 -4.85 (-0.29%)
20-Apr-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.35
Dr. Reddys Lab 1236.85
Cipla 1232.80
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×